| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aims & scope/editorial board
|
|
|
2008
|
21 |
1 |
p. iii-
1 p.
|
artikel
|
| 2 |
Apoptosis in leukemia: From molecular pathways to targeted therapies
|
Schimmer, Aaron D.
|
|
2008
|
21 |
1 |
p. 5-11
7 p.
|
artikel
|
| 3 |
Are there effective new strategies for the treatment of acute and chronic GvHD?
|
Chao, Nelson J.
|
|
2008
|
21 |
1 |
p. 93-98
6 p.
|
artikel
|
| 4 |
Can FLT3 inhibitors overcome resistance in AML?
|
Tam, Winnie F.
|
|
2008
|
21 |
1 |
p. 13-20
8 p.
|
artikel
|
| 5 |
Consolidation therapy: What should be the standard of care?
|
Rowe, Jacob M.
|
|
2008
|
21 |
1 |
p. 53-60
8 p.
|
artikel
|
| 6 |
Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML?
|
Willman, Cheryl L.
|
|
2008
|
21 |
1 |
p. 21-28
8 p.
|
artikel
|
| 7 |
Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): When, how and for whom?
|
Marcondes, Mario
|
|
2008
|
21 |
1 |
p. 67-77
11 p.
|
artikel
|
| 8 |
Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML)
|
Appelbaum, Frederick R.
|
|
2008
|
21 |
1 |
p. 85-92
8 p.
|
artikel
|
| 9 |
Index
|
|
|
2008
|
21 |
1 |
p. I-II
nvt p.
|
artikel
|
| 10 |
Is it important to decipher the heterogeneity of “normal karyotype AML”?
|
Nimer, Stephen D.
|
|
2008
|
21 |
1 |
p. 43-52
10 p.
|
artikel
|
| 11 |
New approaches in acute myeloid leukemia
|
Blum, William
|
|
2008
|
21 |
1 |
p. 29-41
13 p.
|
artikel
|
| 12 |
Older adults: Should the paradigm shift from standard therapy?
|
Estey, Elihu H.
|
|
2008
|
21 |
1 |
p. 61-66
6 p.
|
artikel
|
| 13 |
Should all unrelated donors for transplantation be matched?
|
Weisdorf, Daniel
|
|
2008
|
21 |
1 |
p. 79-83
5 p.
|
artikel
|
| 14 |
Why is clinical progress in acute myelogenous leukemia so slow?
|
Rowe, Jacob M.
|
|
2008
|
21 |
1 |
p. 1-3
3 p.
|
artikel
|
Tijdschrift beschrijving